| Nov 15 |
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
|
| Nov 13 |
Structure Therapeutics reports Q3 results
|
| Nov 13 |
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights
|
| Nov 13 |
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity
|
| Oct 31 |
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024
|
| Oct 24 |
GPCR drugmaker Septerna amasses $288M in IPO
|
| Oct 23 |
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
|
| Oct 22 |
Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients
|
| Oct 21 |
Top small-cap stock picks from Morgan Stanley following the group's upgrade to neutral
|
| Oct 16 |
Structure Therapeutics (GPCR): Innovating Oral Therapies for Obesity and Diabetes
|
